Hospital-Based Cell Processing Facility
"Full-Scale Launch of CRDMO Business"

Organoid Science has established a hospital-based cell processing facility within Asan Medical Center in Seoul and is ramping up its CRDMO business.

From the left: Yang Seunghye, Director at Organoid Science; Kim Taewon, Director of the Asan Institute for Life Sciences; Park Seungil, Hospital Director at Seoul Asan Hospital; Oh Sanghun, CEO of Organoid Science; Shin Dongmyeong, Director of the Cell Therapy Center at Seoul Asan Hospital; and Song Donghun, Director at Organoid Science, are taking a commemorative photo at the opening ceremony of "Onyx Biofoundry". Organoid Science

From the left: Yang Seunghye, Director at Organoid Science; Kim Taewon, Director of the Asan Institute for Life Sciences; Park Seungil, Hospital Director at Seoul Asan Hospital; Oh Sanghun, CEO of Organoid Science; Shin Dongmyeong, Director of the Cell Therapy Center at Seoul Asan Hospital; and Song Donghun, Director at Organoid Science, are taking a commemorative photo at the opening ceremony of "Onyx Biofoundry". Organoid Science

View original image

Organoid Science announced on the 9th that it held an opening ceremony on the 6th at the Convergence Research Building of the Asan Institute for Life Sciences at Asan Medical Center in Seoul for its hospital-based cell processing facility, "Onyx Biofoundry AMC (Asan Medical Center)," and has officially begun operations.


The event was attended by Park Seungil, President of Asan Medical Center; Kim Taewon, Director of the Asan Institute for Life Sciences; and Shin Dongmyeong, Head of the Cell Therapy Center, as well as key figures from the hospital and the company, including Organoid Science CEO Oh Sanghun. The company explained that the event served as an opportunity to share the significance of building an integrated research–clinical infrastructure through collaboration between the hospital and the company.


Onyx Biofoundry AMC is a core hub of the hospital-based CRDMO (Contract Research, Development and Manufacturing Organization) platform that Organoid Science is promoting. It is designed to support clinical research in accordance with the Advanced Regenerative Bio Act and other relevant regulations, and is characterized by an integrated development system that connects research, process development, manufacturing, and clinical stages in conjunction with existing manufacturing facilities.


Because the facility is located inside the hospital, cell-based therapies developed by researchers can be directly manufactured for research or clinical use. Another strength is that development strategies can be adjusted in real time through consultations with medical staff, thereby enhancing the efficiency of translational research. The goal is to rapidly bridge laboratory-stage data to the clinical stage.



Oh Sanghun, CEO of Organoid Science, said, "Building a therapeutic production facility within Asan Medical Center, which has world-class clinical capabilities, is an important milestone that organically links research and clinical practice," adding, "The clinical outcomes generated here will contribute not only to new drug development but also to enhancing the global competitiveness of Korea's advanced bio industry."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing